Hereditary cancer predisposition associated with CHEK2 is caused by heterozygous variants that reduce the function of the CHK2 kinase. It is inherited in an autosomal dominant manner and primarily increases the risk of female breast cancer and, to a lesser extent, prostate cancer. Disruption of the DNA damage response promotes the accumulation of genomic lesions and tumor transformation.
Hereditary cancer (CHEK2 gene)
The CHEK2 gene encodes the CHK2 checkpoint kinase, a tumor suppressor protein activated by double-strand DNA breaks. After being phosphorylated by ATM, it acts on p53, BRCA1, and other proteins to arrest the cell cycle, facilitate repair, or induce apoptosis.
Pathogenic variants with loss of function reduce this response and allow genetic alterations to accumulate. Penetrance is incomplete and depends on the variant, family history, and other modifiers. The average risk of breast cancer is estimated to be around 20-30%, although it typically varies between 15% and 40%. The risk of prostate cancer appears to increase approximately twofold. Clinically relevant risks for other tumors have not been confirmed. The c.1100delC variant is particularly frequent in Northern Europe and reaches nearly 1% in the Netherlands.
Symptoms
Carrier individuals do not present symptoms before developing a tumor. Breast cancer usually appears in adulthood and is frequently estrogen receptor positive; it also increases the risk of a second tumor in the contralateral breast, especially after a diagnosis at a young age. In males, prostate cancer may appear and a small increase in male breast cancer has been described. The age of onset and progression are variable, and many carrier individuals never develop cancer.
Disease management
There is no treatment that eliminates genetic predisposition. Management is based on estimating individual risk and promoting early detection. In women, annual mammography is usually recommended from age 40; magnetic resonance imaging may be considered from age 30-35 depending on family history and local guidelines. Risk-reducing mastectomy is not routinely indicated and is reserved for selected cases. In men, annual PSA may be considered from age 40, especially with a family history. For colorectal cancer and other tumors, population recommendations apply. Cancers are treated according to usual protocols, and there is insufficient evidence to indicate targeted therapies, including PARP inhibitors, solely for a CHEK2 variant.
Genes analyzed
Bibliography
Hanson H, Pal T, Tischkowitz M, Stewart D. CHEK2-Related Cancer Predisposition. GeneReviews®. 2025 [updated 2026].
Hanson H, Astiazaran-Symonds E, Amendola LM, et al. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics. Genet Med. 2023;25(10):100870.
Dorling L, Carvalho S, Allen J, et al. Breast Cancer Risk Genes —Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428-439.
Yadav S, Boddicker NJ, Na J, et al. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023;41(9):1703-1713.
